$462.1MRank #480 on ASXHealthcareMedical - Healthcare Information Services
Prices updated 22 June 2026, 10:40 am AEST · Data: Financial Modeling Prep
Market Cap
$462.1M
Volume
58K
P/E Ratio
20.94
EPS
$0.027
Dividend Yield
0.59%
52-Week High
$2.97
52-Week Low
$1.35
Beta
0.131
Cogstate (ASX: CGS) is an Australian-listed company in the Healthcare sector with a market capitalisation of $462.1M and the 480th-largest security on the ASX by market capitalisation. The CGS share price is $2.72, down 1.09% today and up 100.73% over the past 12 months. Shares have traded between $1.35 and $2.97 over the past 52 weeks. CGS trades on a price-to-earnings ratio of 20.94, above the Healthcare sector median of 14.96, and pays a trailing dividend yield of 0.59%. In its most recent reported period (ending 31 Dec 2025), Cogstate reported revenue of $39.3M and a net profit of $6.9M (17.6% margin).
Charts
$2.75
24H Range
$2.72
$2.75
52-Week Range
$1.35
$2.97
About Cogstate Limited
Melbourne, Australia-based Cogstate Limited, established in 1999, is a neuroscience technology company specializing in computerized cognitive assessments and digital solutions for clinical outcome evaluations. Its comprehensive suite of cognitive services includes project and data management, scientific consulting, statistical analysis, procurement of assessment scales, rater training, and monitoring solutions. The company operates through two distinct divisions. The Clinical Trials segment delivers technology and support services designed to measure the impact of diseases, pharmaceuticals, medical devices, or other interventions on human participants in clinical studies, primarily serving pharmaceutical and biotechnology clients. Concurrently, its Healthcare segment offers Cognigram, a system facilitating regular and standardized testing to assist primary care physicians and hospitals in the early identification of cognitive decline. By June 30, 2022, Cogstate had participated in an estimated 1,800 academic research initiatives.
